接受不同代標靶藥物之晚期肺癌病人於皮膚不良事件、自我照顧能力與情緒狀態之探討

Skin Adverse Events, Ability of Self-Care and Psychological Status in Patients with Lung Cancer Receiving Different Generation Targeted Therapies

10.6342/NTU202000722

游竹君

肺癌 ； 標靶治療 ； 皮膚不良事件 ； 自我照顧 ； 情緒狀態 ； lung cancer ； targeted therapy ； skin adverse event ； self-care ； psychological state

臺灣大學護理學研究所學位論文

2020年

碩士

李芸湘

繁體中文

標靶治療為晚期肺癌病人重要的抗癌治療之一，表皮生長因子受體酪胺酸激酶抑制劑（EGFR-TKI）常見之副作用為皮膚不良事件，隨著標靶藥物不斷推陳出新，不同代EGFR-TKI引起之皮膚不良事件發生比例、自我照顧能力與情緒狀態差異的相關研究，仍十分缺乏，故本研究主要目的為探討晚期肺癌病人接受不同代標靶藥物於皮膚不良事件、自我照顧能力及情緒狀態的現況及差異。 本研究為橫斷式描述性相關研究設計，以立意取樣方式，於北部某醫學中心皮膚科及腫瘤治療藥物疹特別門診進行收案，共收案135位，使用結構式問卷包括：基本資料量表、客觀指標之美國國家癌症研究所（NCI）公佈的不良事件常用術語標準（CTCAE v4.03）及主觀指標之患者報告的結果版本（PRO-CTCAE ITEMS Version 1.0）、醫院焦慮憂鬱量表（HADS）與情緒溫度計（DT）、自我照顧能力及自我照顧策略量表收集資料，以描述性及推論性統計進行資料分析。 研究結果顯示：（1）99.3 %病患出現皮膚不良事件，發生率前三名依序為搔癢、乾燥及痤瘡樣疹，嚴重度多落在grade I至grade II之間；（2）整體情緒困擾（DT）平均分數為3.3分；31.1 %病患有重度焦慮、憂鬱傾向；（3）皮膚不良事件之自我照顧能力平均分數為6.9分，而最常使用之自我照顧策略為：使用醫生開立的藥物、藥妝店買得乳液及手邊現成皮膚科的藥物；（4）皮膚不良事件之搔癢、乾燥、痤瘡樣疹、手足症候群、脫髮與DT呈現正相關；皮膚自我照顧能力與DT呈現負相關性；（5）第三代EGFR-TKI病患之痤瘡樣疹發生率於客觀評量（CTCAE）結果顯著比第一代少，主觀評量（PRO-CTCAE）嚴重度則比第一、二代好；（6）接受第三代EGFR-TKI病患之DT顯著比第一代表現輕微。 本研究所探討使用標靶治療之肺癌病患皮膚不良事件、自我照顧能力與策略，以及情緒狀態，有助於臨床人員更進一步了解不同代標靶藥物於皮膚不良事件與情緒狀態之差異，可提供學術及臨床照護上具體參考依據。

Background Targeted therapy is now a predominant treatment method for advanced lung cancer. The side effect of EGFR inhibitors is one of the manifestations of skin adverse events. As new targeted therapy programs for lung cancer have been developed, diverse generation of target medicine has induced the similar adverse events of skin toxicity. However, the reported incidents were lack of comparison and investigation, especially skin reactions. The purpose of this report is to understand diverse skin adverse reactions on advanced lung cancer patient with experience of targeted therapy, and to discuss their self-care ability and psychological distress. Therefore, this article has also examined the differences of skin adverse events, the level of patient self -care ability, and the level of psychological state in selected lung cancer patients treated by various targeted therapy medicine. Method This article is presented as a descriptive correlation research which was designed as cross-sectional design and purposive sampling of 135 patients. Structured questionnaires including patient details and objective data are collected through CTCAE v4.03 from NCI. Subjectively, PRO-CTCAE ITEMS Version 1.0, Hospital Anxiety and Depression Scale, Distress Thermometer (DT), Self-Care Ability Scale, and Effective Self-Care Strategies Scale are all involved as data collection in dermatology and oncology outpatient medical center at a Taiwan hospital in north. Consequently, inferential and descriptive statistics conclude the data analysis by Fisher’s Exact Test, Kruskal-Wallis test and Spearman Correlation. Results 　　The results showed (1) 99.3% of patients had dermatologic toxicities. The top three incidences of these skin adverse events were pruritus, dry skin and papulopustular eruption. The severity of these symptoms is between grade I to grade II. (2) Tools: DT score was 3.3 (±2.5)；31.1% of patients had severe anxiety and depression. (3) The self-care ability of skin adverse reactions score was 6.9. The most common self-care approaches to skin adverse events were first using prescription drugs by Dermatologists, applying topical cream over the counter comes after, and using pre-purchased dermatology medicine at the end. (4) Subject skin adverse events, including pruritus, dry skin, papulopustular eruption, hand-foot syndrome and hair loss have positive correlation to distress thermometer score. The ability of skin self-care has negative correlation to distress thermometer score. (5) The incidence rate of papulopustular eruption in the third generation of EGFR-TKI patient was significantly lesser than the first generation use as CTCAE examined. The severity of this sympton in the third generation drug was lesser than other two generations as Pro-CTCAE presented. (6) The DT score of the third generation of EGFR-TKI patient showed less stressed but differed significantly than the first generation. Conclusion Findings above have already summarized the reported skin adverse events in advanced lung cancer patients regarding the ability and strategy of self-care and the subjective opinions of psychological status. To investigate more relations between three different targeted drugs and patient skin care physically and mentally, the longitudinal studies would be necessary as references in nursing care to benefit patient care and medical research.

1. Agero, A. L., Dusza, S. W., Benvenuto-Andrade, C., Busam, K. J., Myskowski, P., & Halpern, A. C. (2006). Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. Journal of the American Academy of Dermatology, 55(4), 657-670. doi:10.1016/j.jaad.2005.10.010
   連結：
2. Almonacid, C. I., Ramos, A. J., & Rodriguez-Borrego, M. A. (2016). Level of anxiety versus self-care in the preoperative and postoperative periods of total laryngectomy patients. Revista Latino-Americana de Enfermagem, 24, e2707, doi:10.1590/1518-8345.0743.2707
   連結：
3. Annunziata, M. C., Ferrillo, M., Cinelli, E., Panariello, L., Rocco, D., & Fabbrocini, G. (2019). Retrospective Analysis of Skin Toxicity in Patients under Anti-EGFR Tyrosine Kinase Inhibitors: Our Experience in Lung Cancer. Open Access Macedonian Journal of Medical Sciences, 7(6), 973-977. doi:10.3889/oamjms.2019.170
   連結：
4. Aprile, G., Pisa, F. E., Follador, A., Foltran, L., De Pauli, F., Mazzer, M., . . . Fasola, G. (2013). Unplanned presentations of cancer outpatients: a retrospective cohort study. Supportive Care in Cancer, 21(2), 397-404. doi:10.1007/s00520-012-1524-6
   連結：
5. Arrieta, O., Angulo, L. P., Nunez-Valencia, C., Dorantes-Gallareta, Y., Macedo, E. O., Martinez-Lopez, D., . . . Onate-Ocana, L. F. (2013). Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer. Annals of Surgical Oncology, 20(6), 1941–1948. doi:10.1245/s10434-012-2793-5
   連結：
6. Bagheri-Nesami, M., Goudarzian, A. H., Mirani, H., Jouybari, S. S., & Nasiri, D. (2016). Association between Self-Care Behaviors and Self-Esteem of Rural Elderlies; Necessity of Health Promotion. Materia Socio-Medica, 28(1), 41-45. doi:10.5455/msm.2016.28.41-45
   連結：
7. Balagula, Y., Garbe, C., Myskowski, P. L., Hauschild, A., Rapoport, B. L., Boers-Doets, C. B., & Lacouture, M. E. (2011). Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. International Journal of Dermatology, 50(2), 129-146. doi:10.1111/j.1365-4632.2010.04791.x
   連結：
8. Barton-Burke, M., Ciccolini, K., Mekas, M., & Burke, S. (2017). Dermatologic Reactions to Targeted Therapy: A Focus on Epidermal Growth Factor Receptor Inhibitors and Nursing Care. Nursing Clinics of North America, 52(1), 83-113. doi:10.1016/j.cnur.2016.11.005
   連結：
9. Basch, E., Dueck, A. C., Rogak, L. J., Minasian, L. M., Kelly, W. K., O'Mara, A. M., . . . Schrag, D. (2017). Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncology, 3(8), 1043-1050. doi:10.1001/jamaoncol.2016.6749
   連結：
10. Basch, E., Jia, X., Heller, G., Barz, A., Sit, L., Fruscione, M., . . . Schrag, D. (2009). Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. Journal of the National Cancer Institute, 101(23), 1624-1632. doi:10.1093/jnci/djp386
    連結：
11. Basch, E., Reeve, B. B., Mitchell, S. A., Clauser, S. B., Minasian, L. M., Dueck, A. C., . . . Schrag, D. (2014). Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Journal of the National Cancer Institute, 106(9). doi:10.1093/jnci/dju244
    連結：
12. Bensadoun, R. J., Humbert, P., Krutman, J., Luger, T., Triller, R., Rougier, A., . . . Dreno, B. (2013). Daily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel. Cancer Management and Research, 5, 401-408. doi:10.2147/CMAR.S52256
    連結：
13. Berger, A., Regueiro, C., Hijal, T., Pasquier, D., De La Fuente, C., Le Tinier, F., . . . Bensadoun, R. J. (2018). Interest of Supportive and Barrier Protective Skin Care Products in the Daily Prevention and Treatment of Cutaneous Toxicity During Radiotherapy for Breast Cancer. Breast Cancer: Basic and Clinical Research, 12, 1178223417752772. doi:10.1177/1178223417752772
    連結：
14. Bernier, J., Russi, E. G., Homey, B., Merlano, M. C., Mesia, R., Peyrade, F., & Budach, W. (2011). Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines. Annals of Oncology, 22(10), 2191-2200. doi:10.1093/annonc/mdr139
    連結：
15. Borczuk, A. C. (2016). Prognostic considerations of the new World Health Organization classification of lung adenocarcinoma. European Respiratory Review, 25(142), 364-371. doi:10.1183/16000617.0089-2016
    連結：
16. Boyes, A. W., Girgis, A., D'Este, C., & Zucca, A. C. (2012). Prevalence and correlates of cancer survivors' supportive care needs 6 months after diagnosis: a population-based cross-sectional study. BMC Cancer, 12, 150. doi:10.1186/1471-2407-12-150
    連結：
17. Bradley, S. H., Kennedy, M. P. T., & Neal, R. D. (2019). Recognising Lung Cancer in Primary Care. Advances in Therapy, 36(1), 19-30. doi:10.1007/s12325-018-0843-5
    連結：
18. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394-424. doi:10.3322/caac.21492
    連結：
19. Califano, R., Tariq, N., Compton, S., Fitzgerald, D. A., Harwood, C. A., Lal, R., . . . Nicolson, M. (2015). Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK. Drugs, 75(12), 1335-1348. doi:10.1007/s40265-015-0434-6
    連結：
20. Chan, J. C., Lee, Y. H., Liu, C. Y., Shih, H. H., Tsay, P. K., & Tang, W. R. (2019). A Correlational Study of Skin Toxicity and Quality of Life in Patients With Advanced Lung Cancer Receiving Targeted Therapy. Journal of Nursing Research, 27(6), e51. doi:10.1097/jnr.0000000000000339
    連結：
21. Chandrasekar, D., Tribett, E., & Ramchandran, K. (2016). Integrated Palliative Care and Oncologic Care in Non-Small-Cell Lung Cancer. Current Treatment Options in Oncology, 17(5), 23. doi:10.1007/s11864-016-0397-1
    連結：
22. Chen, K.-L., Lin, C.-C., Cho, Y.-T., Yang, C.-W., Sheen, Y.-S., Tsai, H.-E., & Chu, C.-Y. (2016). Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non–Small Cell Lung Cancer. JAMA Dermatology, 152(3), 340-342. doi:10.1001/jamadermatol.2015.4448
    連結：
23. Chou, F. Y., Dodd, M., Abrams, D., & Padilla, G. (2007). Symptoms, self-care, and quality of life of Chinese American patients with cancer. Oncology Nursing Forum, 34(6), 1162-1167. doi:10.1188/07.ONF.1162-1167
    連結：
24. Chu, C. Y., Chen, K. Y., Wen-Cheng Chang, J., Wei, Y. F., Lee, C. H., & Wang, W. M. (2017). Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities. Journal of the Formosan Medical Association, 116(6), 413-423. doi:10.1016/j.jfma.2017.03.001
    連結：
25. Chu, C. Y., Choi, J., Eaby-Sandy, B., Langer, C. J., & Lacouture, M. E. (2018). Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer. Oncologist, 23(8), 891-899. doi:10.1634/theoncologist.2017-0582
    連結：
26. Cnossen, I. C., van Uden-Kraan, C. F., Eerenstein, S. E., Jansen, F., Witte, B. I., Lacko, M., . . . Verdonck-de Leeuw, I. M. (2016). An online self-care education program to support patients after total laryngectomy: feasibility and satisfaction. Supportive Care in Cancer, 24(3), 1261-1268. doi:10.1007/s00520-015-2896-1
    連結：
27. D'Arcangelo, M., & Hirsch, F. R. (2014). Clinical and comparative utility of afatinib in non-small cell lung cancer. Biologics: Targets and Therapy, 8, 183-192. doi:10.2147/BTT.S40567
    連結：
28. Dagogo-Jack, I., Azzolli, C. G., Fintelmann, F., Mino-Kenudson, M., Farago, A. F., Gainor, J. F., . . . Lennerz, J. K. (2018). Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precision Oncology, 2018. doi:10.1200/PO.17.00299
    連結：
29. Davidson, P. M., Daly, J., Hancock, K., Moser, D., Chang, E., & Cockburn, J. (2003). Perceptions and experiences of heart disease: a literature review and identification of a research agenda in older women. European Journal of Cardiovascular Nursing, 2(4), 255-264. doi:10.1016/S1474-5151(03)00056-2
    連結：
30. Detterbeck, F. C. (2018). The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Journal of Thoracic and Cardiovascular Surgery, 155(1), 356-359. doi:10.1016/j.jtcvs.2017.08.138
    連結：
31. Detterbeck, F. C., Boffa, D. J., Kim, A. W., & Tanoue, L. T. (2017). The Eighth Edition Lung Cancer Stage Classification. Chest, 151(1), 193-203. doi:10.1016/j.chest.2016.10.010
    連結：
32. Di Mattei, V. E., Carnelli, L., Taranto, P., Bernardi, M., Brombin, C., Cugnata, F., . . . Candiani, M. (2017). "Health in the Mirror": An Unconventional Approach to Unmet Psychological Needs in Oncology. Frontiers in Psychology, 8, 1633. doi:10.3389/fpsyg.2017.01633
    連結：
33. Dodd, M. J. (1984). Self-care for patients with breast cancer to prevent side effects of chemotherapy: a concern for public health nursing. Public Health Nursing, 1(4), 202-209. doi:10.1111/j.1525-1446.1984.tb00454.x
    連結：
34. Dueck, A. C., Mendoza, T. R., Mitchell, S. A., Reeve, B. B., Castro, K. M., Rogak, L. J., . . . National Cancer Institute, P. R. O. C. S. G. (2015). Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncology, 1(8), 1051-1059. doi:10.1001/jamaoncol.2015.2639
    連結：
35. Ensslin, C. J., Rosen, A. C., Wu, S., & Lacouture, M. E. (2013). Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. Journal of the American Academy of Dermatology, 69(5), 708-720. doi:10.1016/j.jaad.2013.06.038
    連結：
36. Fabbrocini, G., Cameli, N., Romano, M. C., Mariano, M., Panariello, L., Bianca, D., & Monfrecola, G. (2012). Chemotherapy and skin reactions. Journal of Experimental & Clinical Cancer Research, 31(1), 50. doi:10.1186/1756-9966-31-50
    連結：
37. Fabbrocini, G., Panariello, L., Caro, G., & Cacciapuoti, S. (2015). Acneiform Rash Induced by EGFR Inhibitors: Review of the Literature and New Insights. Skin Appendage Disorders, 1(1), 31-37. doi:10.1159/000371821
    連結：
38. Finney Rutten, L. J., Agunwamba, A. A., Wilson, P., Chawla, N., Vieux, S., Blanch-Hartigan, D., . . . Hesse, B. W. (2016). Cancer-Related Information Seeking Among Cancer Survivors: Trends Over a Decade (2003-2013). Journal of Cancer Education, 31(2), 348-357. doi:10.1007/s13187-015-0802-7
    連結：
39. Friedman, T., Quencer, K. B., Kishore, S. A., Winokur, R. S., & Madoff, D. C. (2017). Malignant Venous Obstruction: Superior Vena Cava Syndrome and Beyond. Seminars in Interventional Radiology, 34(4), 398-408. doi:10.1055/s-0037-1608863
    連結：
40. Funk, R., Cisneros, C., Williams, R. C., Kendall, J., & Hamann, H. A. (2016). What happens after distress screening? Patterns of supportive care service utilization among oncology patients identified through a systematic screening protocol. Supportive Care in Cancer, 24(7), 2861-2868. doi:10.1007/s00520-016-3099-0
    連結：
41. Galimont-Collen, A. F., Vos, L. E., Lavrijsen, A. P., Ouwerkerk, J., & Gelderblom, H. (2007). Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. European Journal of Cancer, 43(5), 845-851. doi:10.1016/j.ejca.2006.11.016
    連結：
42. Gao, W., Bennett, M. I., Stark, D., Murray, S., & Higginson, I. J. (2010). Psychological distress in cancer from survivorship to end of life care: prevalence, associated factors and clinical implications. European Journal of Cancer, 46(11), 2036-2044. doi:10.1016/j.ejca.2010.03.033
    連結：
43. Gaston-Johansson, F., Fall-Dickson, J. M., Nanda, J. P., Sarenmalm, E. K., Browall, M., & Goldstein, N. (2013). Long-term effect of the self-management comprehensive coping strategy program on quality of life in patients with breast cancer treated with high-dose chemotherapy. Journal of Psychosocial Oncology, 22(3), 530-539. doi:10.1002/pon.3031
    連結：
44. Gerber, P. A., Buhren, B. A., Cevikbas, F., Bolke, E., Steinhoff, M., & Homey, B. (2010). Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor-induced pruritus. Journal of the American Academy of Dermatology, 63(1), 163-165. doi:10.1016/j.jaad.2009.09.023
    連結：
45. Goudarzian, A. H., Bagheri Nesami, M., Zamani, F., Nasiri, A., & Beik, S. (2017). Relationship between Depression and Self-care in Iranian Patients with Cancer. Asian Pacific Journal of Cancer Prevention, 18(1), 101-106. doi:10.22034/APJCP.2017.18.1.101
    連結：
46. Goudarzian, A. H., Boyle, C., Beik, S., Jafari, A., Bagheri Nesami, M., Taebi, M., & Zamani, F. (2019). Self-Care in Iranian Cancer Patients: The Role of Religious Coping. Journal of Religion and Health, 58(1), 259-270. doi:10.1007/s10943-018-0647-6
    連結：
47. Grey, M., Knafl, K., & McCorkle, R. (2006). A framework for the study of self- and family management of chronic conditions. Nursing Outlook, 54(5), 278-286. doi:10.1016/j.outlook.2006.06.004
    連結：
48. Gridelli, C., Rossi, A., Carbone, D. P., Guarize, J., Karachaliou, N., Mok, T., . . . Rosell, R. (2015). Non-small-cell lung cancer. Nature Reviews Disease Primers, 1, 15009. doi:10.1038/nrdp.2015.9
    連結：
49. Haley, A. C., Calahan, C., Gandhi, M., West, D. P., Rademaker, A., & Lacouture, M. E. (2011). Skin care management in cancer patients: an evaluation of quality of life and tolerability. Support Care in Cancer, 19(4), 545-554. doi:10.1007/s00520-010-0851-8
    連結：
50. Hamer, M., Chida, Y., & Molloy, G. J. (2009). Psychological distress and cancer mortality. Journal of Psychosomatic Research, 66(3), 255-258. doi:10.1016/j.jpsychores.2008.11.002
    連結：
51. Heo, S., Moser, D. K., Lennie, T. A., Riegel, B., & Chung, M. L. (2008). Gender differences in and factors related to self-care behaviors: a cross-sectional, correlational study of patients with heart failure. International Journal of Nursing Studies, 45(12), 1807-1815. doi:10.1016/j.ijnurstu.2008.05.008
    連結：
52. Hirayama, K., Su, Y., Ikezawa, Y., Chiba, M., Ito, K., & Yuki, M. (2019). Association between Subjective Evaluation of Skin Toxicities and Quality of Life in Patients with Lung Cancer Undergoing Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Pilot Study for Developing Skin Toxicity Assessment. Open Journal of Nursing, 9(12), 1226-1239. doi:10.4236/ojn.2019.912089
    連結：
53. Hofheinz, R. D., Deplanque, G., Komatsu, Y., Kobayashi, Y., Ocvirk, J., Racca, P., . . . Jatoi, A. (2016). Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors. Oncologist, 21(12), 1483-1491. doi:10.1634/theoncologist.2016-0051
    連結：
54. Holcmann, M., & Sibilia, M. (2015). Mechanisms underlying skin disorders induced by EGFR inhibitors. Molecular and Cellular Oncology, 2(4), e1004969. doi:10.1080/23723556.2015.1004969
    連結：
55. Hrustanovic, G., Lee, B. J., & Bivona, T. G. (2013). Mechanisms of resistance to EGFR targeted therapies. Cancer Biology & Therapy, 14(4), 304-314. doi:10.4161/cbt.23627
    連結：
56. Hu, J. C., Sadeghi, P., Pinter-Brown, L. C., Yashar, S., & Chiu, M. W. (2007). Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. Journal of the American Academy of Dermatology, 56(2), 317-326. doi:10.1016/j.jaad.2006.09.005
    連結：
57. Inamura, K. (2017). Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification. Frontiers in Oncology, 7, 193. doi:10.3389/fonc.2017.00193
    連結：
58. Inamura, K. (2018). Update on Immunohistochemistry for the Diagnosis of Lung Cancer. Cancers, 10(3), 72. doi:10.3390/cancers10030072
    連結：
59. Jacobsen, P. B., & Jim, H. S. (2008). Psychosocial interventions for anxiety and depression in adult cancer patients: achievements and challenges. CA: A Cancer Journal for Clinicians, 58(4), 214-230. doi:10.3322/CA.2008.0003
    連結：
60. Jatoi, A., Green, E. M., Rowland, K. M., Jr., Sargent, D. J., & Alberts, S. R. (2009). Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology, 77(2), 120-123. doi:10.1159/000229751
    連結：
61. Joshi, S. S., Ortiz, S., Witherspoon, J. N., Rademaker, A., West, D. P., Anderson, R., . . . Lacouture, M. E. (2010). Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer, 116(16), 3916-3923. doi:10.1002/cncr.25090
    連結：
62. Kalemkerian, G. P., Narula, N., & Kennedy, E. B. (2018). Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement Summary of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. Journal of Oncology Practice, 14(5), 323-327. doi:10.1200/JOP.18.00035
    連結：
63. Keating, G. M. (2014). Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer. Drugs, 74(2), 207-221. doi:10.1007/s40265-013-0170-8
    連結：
64. Kiyohara, Y., Yamazaki, N., & Kishi, A. (2013). Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer. Journal of the American Academy of Dermatology, 69(3), 463-472. doi:10.1016/j.jaad.2013.02.025
    連結：
65. Knobf, M. T., Cooley, M. E., Duffy, S., Doorenbos, A., Eaton, L., Given, B., . . . Mallory, G. (2015). The 2014-2018 Oncology Nursing Society Research Agenda. Oncology Nursing Forum, 42(5), 450-465. doi:10.1188/15.ONF.450-465
    連結：
66. Kozuki, T. (2016). Skin problems and EGFR-tyrosine kinase inhibitor. Japanese Journal of Clinical Oncology, 46(4), 291-298. doi:10.1093/jjco/hyv207
    連結：
67. Kumar, S., Juresic, E., Barton, M., & Shafiq, J. (2010). Management of skin toxicity during radiation therapy: a review of the evidence. Journal of Medical Imaging and Radiation Oncology, 54(3), 264-279. doi:10.1111/j.1754-9485.2010.02170.x
    連結：
68. Lüftner, D., Dell'Acqua, V., Selle, F., Khalil, A., Leonardi, M. C., De La Torre Tomás, A., . . . Seité, S. (2018). Evaluation of supportive and barrier-protective skin care products in the daily prevention and treatment of cutaneous toxicity during systemic chemotherapy. OncoTargets and Therapy, 11, 5865-5872. doi:10.2147/OTT.S155438
    連結：
69. Lacouture, M. E. (2006). Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature Reviews Cancer, 6(10), 803-812. doi:10.1038/nrc1970
    連結：
70. Lacouture, M. E., Anadkat, M. J., Bensadoun, R. J., Bryce, J., Chan, A., Epstein, J. B., . . . Group, M. S. T. S. (2011). Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Supportive Care in Cancer, 19(8), 1079-1095. doi:10.1007/s00520-011-1197-6
    連結：
71. Langer, C. J., Besse, B., Gualberto, A., Brambilla, E., & Soria, J. C. (2010). The evolving role of histology in the management of advanced non-small-cell lung cancer. Journal of Clinical Oncology, 28(36), 5311-5320. doi:10.1200/JCO.2010.28.8126
    連結：
72. Lee, S. H., Lee, K. H., & Chang, S. J. (2018). Do health literacy and self-care behaviours affect quality of life in older persons with lung cancer receiving chemotherapy? International Journal of Nursing Practice, 24(6), e12691. doi:10.1111/ijn.12691
    連結：
73. Liang, H., Liu, X., & Wang, M. (2018). Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment. OncoTargets and Therapy, 11, 6189-6196. doi:10.2147/OTT.S178497
    連結：
74. Liao, Y. C., Liao, W. Y., Sun, J. L., Ko, J. C., & Yu, C. J. (2018). Psychological distress and coping strategies among women with incurable lung cancer: a qualitative study. Supportive Care in Cancer, 26(3), 989-996. doi:10.1007/s00520-017-3919-x
    連結：
75. Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., . . . Ladanyi, M. (2013). Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Archives of Pathology & Laboratory Medicine, 137(6), 828-860. doi:10.5858/arpa.2012-0720-OA
    連結：
76. Linden, W., Vodermaier, A., Mackenzie, R., & Greig, D. (2012). Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. Journal of Affective Disorders, 141(2-3), 343-351. doi:10.1016/j.jad.2012.03.025
    連結：
77. Losanno, T., Rossi, A., Maione, P., Napolitano, A., & Gridelli, C. (2016). Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer. Expert Opinion on Biological Therapy, 16(6), 747-758. doi:10.1517/14712598.2016.1163333
    連結：
78. Luu, M., Lai, S. E., Patel, J., Guitart, J., & Lacouture, M. E. (2007). Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib. Photodermatology, Photoimmunology & Photomedicine, 23(1), 42-45. doi:10.1111/j.1600-0781.2007.00273.x
    連結：
79. Lynch, T. J., Jr., Kim, E. S., Eaby, B., Garey, J., West, D. P., & Lacouture, M. E. (2007). Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist, 12(5), 610-621. doi:10.1634/theoncologist.12-5-610
    連結：
80. Macdonald, J. B., Macdonald, B., Golitz, L. E., LoRusso, P., & Sekulic, A. (2015). Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane. Journal of the American Academy of Dermatology, 72(2), 203-218. doi:10.1016/j.jaad.2014.07.032
    連結：
81. Mannion, E., Gilmartin, J. J., Donnellan, P., Keane, M., & Waldron, D. (2014). Effect of chemotherapy on quality of life in patients with non-small cell lung cancer. Supportive Care in Cancer, 22(5), 1417-1428. doi:10.1007/s00520-014-2148-9
    連結：
82. Mason, J., Blyth, B., MacManus, M. P., & Martin, O. A. (2017). Treatment for non-small-cell lung cancer and circulating tumor cells. Lung Cancer Management, 6(4), 129-139. doi:10.2217/lmt-2017-0019
    連結：
83. McPhail, S., Johnson, S., Greenberg, D., Peake, M., & Rous, B. (2015). Stage at diagnosis and early mortality from cancer in England. British Journal of Cancer, 112(1), S108–S115. doi:10.1038/bjc.2015.49
    連結：
84. Mehnert, A., Hartung, T. J., Friedrich, M., Vehling, S., Brahler, E., Harter, M., . . . Faller, H. (2018). One in two cancer patients is significantly distressed: Prevalence and indicators of distress. Journal of Psychosocial Oncology, 27(1), 75-82. doi:10.1002/pon.4464
    連結：
85. Melosky, B., Leighl, N. B., Rothenstein, J., Sangha, R., Stewart, D., & Papp, K. (2015). Management of egfr tki-induced dermatologic adverse events. Current Oncology, 22(2), 123-132. doi:10.3747/co.22.2430
    連結：
86. Mercadante, S., & Vitrano, V. (2010). Pain in patients with lung cancer: pathophysiology and treatment. Lung Cancer, 68(1), 10-15. doi:10.1016/j.lungcan.2009.11.004
    連結：
87. Mitchell, A. J. (2007). Pooled results from 38 analyses of the accuracy of distress thermometer and other ultra-short methods of detecting cancer-related mood disorders. Journal of Clinical Oncology, 25(29), 4670-4681. doi:10.1200/JCO.2006.10.0438
    連結：
88. Molassiotis, A., Lowe, M., Blackhall, F., & Lorigan, P. (2011). A qualitative exploration of a respiratory distress symptom cluster in lung cancer: cough, breathlessness and fatigue. Lung Cancer, 71(1), 94-102. doi:10.1016/j.lungcan.2010.04.002
    連結：
89. Morrison, E. J., Novotny, P. J., Sloan, J. A., Yang, P., Patten, C. A., Ruddy, K. J., & Clark, M. M. (2017). Emotional Problems, Quality of Life, and Symptom Burden in Patients With Lung Cancer. Clinical Lung Cancer, 18(5), 497-503. doi:10.1016/j.cllc.2017.02.008
    連結：
90. Muthu, V., Mylliemngap, B., Prasad, K. T., Behera, D., & Singh, N. (2019). Adverse effects observed in lung cancer patients undergoing first-line chemotherapy and effectiveness of supportive care drugs in a resource-limited setting. Lung India, 36(1), 32-37. doi:10.4103/lungindia.lungindia_321_17
    連結：
91. O'Donovan, A., Coleman, M., Harris, R., & Herst, P. (2015). Prophylaxis and management of acute radiation-induced skin toxicity: a survey of practice across Europe and the USA. European Journal of Cancer Care, 24(3), 425-435. doi:10.1111/ecc.12213
    連結：
92. Osio, A., Mateus, C., Soria, J. C., Massard, C., Malka, D., Boige, V., . . . Robert, C. (2009). Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. British Journal of Dermatology, 161(3), 515-521. doi:10.1111/j.1365-2133.2009.09214.x
    連結：
93. Owczarek, W., Slowinska, M., Lesiak, A., Ciazynska, M., Maciag, A., Paluchowska, E., . . . Czajkowski, R. (2017). The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors. Advances in Dermatology and Allergology/Postepy Dermatologii i Alergologii, 34(5), 418-428. doi:10.5114/ada.2017.71106
    連結：
94. Pan, H. H., Lin, K. C., Ho, S. T., Liang, C. Y., Lee, S. C., & Wang, K. Y. (2012). Factors related to daily life interference in lung cancer patients: a cross-sectional regression tree study. European Journal of Oncology Nursing, 16(4), 345-352. doi:10.1016/j.ejon.2011.07.011
    連結：
95. Pirker, R., Pereira, J. R., Szczesna, A., von Pawel, J., Krzakowski, M., Ramlau, R., . . . Team, F. S. (2009). Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. The Lancet, 373(9674), 1525-1531. doi:10.1016/S0140-6736(09)60569-9
    連結：
96. Pozo, C. L., Morgan, M. A., & Gray, J. E. (2014). Survivorship issues for patients with lung cancer. Cancer Control, 21(1), 40-50. doi:10.1177/107327481402100106
    連結：
97. Pugliese, S. B., Neal, J. W., & Kwong, B. Y. (2015). Management of Dermatologic Complications of Lung Cancer Therapies. Current Treatment Options in Oncology, 16(10), 50. doi:10.1007/s11864-015-0368-y
    連結：
98. Ramalingam, S. S., Rukazenkov, Y., Thomas, K., & Soria, J. C. (2015). A randomized, phase III study (FLAURA) of AZD9291, a novel EGFR-TKI, versus gefitinib or erlotinib in treatment-naïve patients with advanced non-small cell lung cancer and an EGFR-TKI-sensitizing mutation. Journal of Clinical Oncology, 33(15_suppl), TPS8102-TPS8102. doi:10.1200/jco.2015.33.15_suppl.tps8102
    連結：
99. Rami-Porta, R., Bolejack, V., Crowley, J., Ball, D., Kim, J., Lyons, G., . . . Participating, I. (2015). The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 10(7), 990-1003. doi:10.1097/JTO.0000000000000559
    連結：
100. Reyes-Habito, C. M., & Roh, E. K. (2014). Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy. Journal of the American Academy of Dermatology, 71(2), 217.e1-217.e11. doi:10.1016/j.jaad.2014.04.013
     連結：
101. Riba, M. B., Donovan, K. A., Andersen, B., Braun, I., Breitbart, W. S., Brewer, B. W., . . . Darlow, S. D. (2019). Distress Management, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 17(10), 1229-1249. doi:10.6004/jnccn.2019.0048
     連結：
102. Richard, A., Harbeck, N., Wuerstlein, R., & Wilhelm, F. H. (2019). Recover your smile: Effects of a beauty care intervention on depressive symptoms, quality of life, and self-esteem in patients with early breast cancer. Psychooncology, 28(2), 401-407. doi:10.1002/pon.4957
     連結：
103. Romito, F., Giuliani, F., Cormio, C., Tulipani, C., Mattioli, V., & Colucci, G. (2010). Psychological effects of cetuximab-induced cutaneous rash in advanced colorectal cancer patients. Supportive Care in Cancer, 18(3), 329-334. doi:10.1007/s00520-009-0656-9
     連結：
104. Rosen, A. C., Case, E. C., Dusza, S. W., Balagula, Y., Gordon, J., West, D. P., & Lacouture, M. E. (2013). Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. American Journal of Clinical Dermatology, 14(4), 327-333. doi:10.1007/s40257-013-0021-0
     連結：
105. Ryan, P., & Sawin, K. J. (2009). The Individual and Family Self-Management Theory: background and perspectives on context, process, and outcomes. Nursing Outlook, 57(4), 217-225 e6. doi:10.1016/j.outlook.2008.10.004
     連結：
106. Santabarbara, G., Maione, P., Rossi, A., & Gridelli, C. (2016). Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy. Expert Opinion on Pharmacotherapy, 17(4), 561-570. doi:10.1517/14656566.2016.1122757
     連結：
107. Sawin, K. J., Weiss, M. E., Johnson, N., Gralton, K., Malin, S., Klingbeil, C., . . . Schiffman, R. F. (2017). Development of a Self-Management Theory-Guided Discharge Intervention for Parents of Hospitalized Children. Journal of Nursing Scholarship, 49(2), 202-213. doi:10.1111/jnu.12284
     連結：
108. Segaert, S., & Van Cutsem, E. (2005). Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Annals of Oncology, 16(9), 1425-1433. doi:10.1093/annonc/mdi279
     連結：
109. Shams, S., Jabbar, A. A., Nanji, K., Jan, R., & Tharani, A. (2018). Influence of supportive care on chemotherapy patients' self-care behaviour and satisfaction: A pilot study conducted in Karachi, Pakistan. Indian Journal of Cancer, 55(1), 115-121. doi:10.4103/ijc.IJC_621_17
     連結：
110. Sharma, J., Shum, E., Chau, V., Paucar, D., Cheng, H., & Halmos, B. (2017). The Evolving Role of Biomarkers in Personalized Lung Cancer Therapy. Respiration, 93(1), 1-14. doi:10.1159/000453086
     連結：
111. Shen, K., Cui, J., Wei, Y., Chen, X., Liu, G., Gao, X., . . . Lin, D. (2018). Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis. Journal of Thoracic Disease, 10(12), 6636-6652. doi:10.21037/jtd.2018.11.72
     連結：
112. Shepherd, F. A., Crowley, J., Van Houtte, P., Postmus, P. E., Carney, D., Chansky, K., . . . Participating, I. (2007). The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. Journal of Thoracic Oncology, 2(12), 1067-1077. doi:10.1097/JTO.0b013e31815bdc0d
     連結：
113. Shi, Y., Au, J. S., Thongprasert, S., Srinivasan, S., Tsai, C. M., Khoa, M. T., . . . Yang, P. C. (2014). A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). Journal of Thoracic Oncology, 9(2), 154-162. doi:10.1097/JTO.0000000000000033
     連結：
114. Shioyama, Y., Nakamura, K., Sasaki, T., Ohga, S., Yoshitake, T., Nonoshita, T., . . . Honda, H. (2013). Clinical results of stereotactic body radiotherapy for Stage I small-cell lung cancer: a single institutional experience. Journal of Radiation Research, 54(1), 108-112. doi:10.1093/jrr/rrs075
     連結：
115. Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, 2019. CA: A Cancer Journal for Clinicians, 69(1), 7-34. doi:10.3322/caac.21551
     連結：
116. Silva, A. P., Coelho, P. V., Anazetti, M., & Simioni, P. U. (2017). Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors. Human Vaccines & Immunotherapeutics, 13(4), 843-853. doi:10.1080/21645515.2016.1249551
     連結：
117. Simoff, M. J., Lally, B., Slade, M. G., Goldberg, W. G., Lee, P., Michaud, G. C., . . . Chawla, M. (2013). Symptom management in patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 143(5 Suppl), e455S-e497S. doi:10.1378/chest.12-2366
     連結：
118. Singer, S., Das-Munshi, J., & Brahler, E. (2010). Prevalence of mental health conditions in cancer patients in acute care--a meta-analysis. Annals of Oncology, 21(5), 925-930. doi:10.1093/annonc/mdp515
     連結：
119. Smith, H. R. (2015). Depression in cancer patients: Pathogenesis, implications and treatment (Review). Oncology Letters, 9(4), 1509-1514. doi:10.3892/ol.2015.2944
     連結：
120. Soria, J. C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., . . . Investigators, F. (2018). Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. New England Journal of Medicine, 378(2), 113-125. doi:10.1056/NEJMoa1713137
     連結：
121. Stern, A. F. (2014). The hospital anxiety and depression scale. Occupational Medicine, 64(5), 393-394. doi:10.1093/occmed/kqu024
     連結：
122. Sun, Y., Ren, Y., Fang, Z., Li, C., Fang, R., Gao, B., . . . Ji, H. (2010). Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. Journal of Clinical Oncology, 28(30), 4616–4620. doi:10.1200/JCO.2010.29.6038
     連結：
123. Testa, U., Castelli, G., & Pelosi, E. (2018). Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells. Cancers, 10(8). doi:10.3390/cancers10080248
     連結：
124. Tischer, B., Bilang, M., Kraemer, M., Ronga, P., & Lacouture, M. E. (2018). A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies. Supportive Care in Cancer, 26(4), 1169-1179. doi:10.1007/s00520-017-3938-7
     連結：
125. Travis, W. D., Brambilla, E., Nicholson, A. G., Yatabe, Y., Austin, J. H. M., Beasley, M. B., . . . Panel, W. H. O. (2015). The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. Journal of Thoracic Oncology, 10(9), 1243-1260. doi:10.1097/JTO.0000000000000630
     連結：
126. Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., . . . Yankelewitz, D. (2011). International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. Journal of Thoracic Oncology, 6(2), 244-285. doi:10.1097/JTO.0b013e318206a221
     連結：
127. Urata, Y., Katakami, N., Morita, S., Kaji, R., Yoshioka, H., Seto, T., . . . Nakanishi, Y. (2016). Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. Journal of Clinical Oncology, 34(27), 3248-3257. doi:10.1200/JCO.2015.63.4154
     連結：
128. Valentine, J., Belum, V. R., Duran, J., Ciccolini, K., Schindler, K., Wu, S., & Lacouture, M. E. (2015). Incidence and risk of xerosis with targeted anticancer therapies. Journal of the American Academy of Dermatology, 72(4), 656-667. doi:10.1016/j.jaad.2014.12.010
     連結：
129. Vodermaier, A., Linden, W., MacKenzie, R., Greig, D., & Marshall, C. (2011). Disease stage predicts post-diagnosis anxiety and depression only in some types of cancer. British Journal of Cancer, 105(12), 1814-1817. doi:10.1038/bjc.2011.503
     連結：
130. Wang, B. Y., Huang, J. Y., Cheng, C. Y., Lin, C. H., Ko, J., & Liaw, Y. P. (2013). Lung cancer and prognosis in taiwan: a population-based cancer registry. Journal of Thoracic Oncology, 8(9), 1128-1135. doi:10.1097/JTO.0b013e31829ceba4
     連結：
131. Wang, G. L., Hsu, S. H., Feng, A. C., Chiu, C. Y., Shen, J. F., Lin, Y. J., & Cheng, C. C. (2011). The HADS and the DT for screening psychosocial distress of cancer patients in Taiwan. Journal of Psychosocial Oncology, 20(6), 639-646. doi:10.1002/pon.1952
     連結：
132. Wang, X. S., Shi, Q., Williams, L. A., Komaki, R., Gomez, D. R., Lin, S. H., . . . Liao, Z. (2016). Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. Journal of Pain and Symptom Management, 51(5), 832-838. doi:10.1016/j.jpainsymman.2015.12.316
     連結：
133. Wegner, R. E., Ahmed, N., Hasan, S., Schumacher, L. Y., & Colonias, A. (2018). Lung stereotactic body radiotherapy after past ablative therapy: a single institution case series. Lung Cancer Management, 7(3), LMT05. doi:10.2217/lmt-2018-0012
     連結：
134. Widakowich, C., de Castro, G., Jr., de Azambuja, E., Dinh, P., & Awada, A. (2007). Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist, 12(12), 1443-1455. doi:10.1634/theoncologist.12-12-1443
     連結：
135. Wu, J., & Lacouture, M. E. (2018). Pruritus Associated with Targeted Anticancer Therapies and Their Management. Dermatologic Clinics, 36(3), 315-324. doi:10.1016/j.det.2018.02.010
     連結：
136. Xiao, C., Polomano, R., & Bruner, D. W. (2013). Comparison between patient-reported and clinician-observed symptoms in oncology. Cancer Nursing, 36(6), E1-E16. doi:10.1097/NCC.0b013e318269040f
     連結：
137. Yan, L., & Yi, X. (2013). The international multidisciplinary classification of lung adenocarcinoma from IASLC/ATS/ERS and problems in clinical practice. Chinese Journal of Lung Cancer, 16(7), 333-338. doi:10.3779/j.issn.1009-3419.2013.07.01
     連結：
138. Yang, J. C., Hirsh, V., Schuler, M., Yamamoto, N., O'Byrne, K. J., Mok, T. S., . . . Sequist, L. V. (2013). Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. Journal of Clinical Oncology, 31(27), 3342-3350. doi:10.1200/JCO.2012.46.1764
     連結：
139. Yang, J. C., Wu, Y. L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., . . . Sequist, L. V. (2015). Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. The Lancet Oncology, 16(2), 141-151. doi:10.1016/S1470-2045(14)71173-8
     連結：
140. 中文文獻
141. 台灣癌症基金會（2017）‧戰勝肺癌 殺手疾病不可怕．取自http://homepage.ntu.edu.tw/~ntuylbme/education/LungCancer.pdf
142. 台灣癌症登記中心（2018）‧台灣10大癌症101-105年新發個案存活率（追蹤至106年）‧取自http://tcr.cph.ntu.edu.tw/main.php?Page=A5B3#t01
143. 吳芷儀（2016）‧非小細胞肺癌之口服標靶治療‧彰基藥訊，24（4），1-4
144. 何肇基（2014）‧肺癌的臨床表現‧聲洋防癌之聲，145，2-6。
145. 林如玉（2009）‧接受標靶治療之肺癌病患的副作用及其與皮膚相關生活品質探討（未發表的碩士論文）‧台北市：國立臺灣大學護理學研究所。
146. 邱惠英、林佑樺、王金洲、陳婉宜、張晃智、林孟志（2016）‧肺癌化學治療後病人照護需求與相關因素之探討‧護理雜誌，63（3），62–72。
147. 施志勳（2016）‧單一切口胸腔鏡手術在肺癌治療的應用‧台北市醫師公會會　刊，60（10），30-36。
148. 施穎銘、洪淑淓、張純琪（2017）‧非小細胞肺癌的免疫治療‧內科學誌，28（5），271-278。
149. 柯獻欽、鄭高珍（2018）‧晚期非小細胞肺癌之化學治療與標靶治療‧內科學誌，29，143-152。
150. 徐偉勛、李日翔、林家齊、楊志新（2014）‧肺癌嶄新標靶治療研究現況‧台灣　　醫學，18（6），688-694。
151. 常佑康（2017）‧肺癌立體定位放射治療‧人醫心傳，26-29。
152. 陳晉興（2004）‧認識肺癌系列三：肺癌的治療‧健康世界，227，98-100。
153. 陳嘉允（2017）‧肺癌標靶藥物副作用之中醫治療病例報告‧中醫藥研究論叢，20（2），165-173。
154. 張黎露、朱家瑜、姜紹青、許麗珠、黃國埕、周文珊…侯秀香（2015）‧標靶治療藥品之皮膚毒性預防及照護指引‧腫瘤護理雜誌，15，47-80。
155. 楊志新（2008）‧晚期非小細胞肺癌的標靶治療‧台灣醫學，12（1），22-26。
156. 詹瑞君（2017）‧口服標靶藥物的肺癌病人之皮膚毒性、情緒狀態與健康相關生活品質長期探討（未發表的碩士論文）‧桃園市：長庚大學護理學研究所。
157. 詹瑞君、廖幼捷、李芸湘、賴裕和（2014）‧接受標靶治療的肺癌病患身體心像改變之臨床照護‧護理雜誌，61（4），90-96。
158. 衛生福利部國民健康署（2015，4月）‧歷年惡性腫瘤發生率（攝護腺癌、肺癌 、大腸直腸癌、女性乳癌、子宮頸癌）．取自http://data.hpa.gov.tw/dataset/143023298038
159. 衛生福利部國民健康署（2018，12月）‧105年癌症登記年報．取自https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=269&pid=10227
160. 衛生福利部統計處（2018，10月）‧106年死因統計年報電子書‧取自https://dep.mohw.gov.tw/DOS/lp-3960-113.html
161. 鄭婷方、鄭吉元、陳琦華、鄧新棠（2012）‧晚期非小細胞肺癌藥物治療現況與未來發展‧藥學雜誌，28（1），93-97。
162. 鄭舒帆（2017）‧肺癌治療的新里程‧奇美醫訊，119，22 - 24。
163. 戴鈺娌、陳貞秀、楊政達、陳綱華、江明珠、唐秀治（2015）‧統合分析晚期非小細胞肺癌病人化學治療期間生活品質變化及其影響因素，台灣癌症醫誌，2（3），224-233。
164.  
165. 英文文獻
166. American Cancer Society. (2018). Global Cancer Facts & Figures 4th Edition. Atlanta: American Cancer Society
167. Ehmann, L. M., Ruzicka, T., & Wollenberg, A. (2011). Cutaneous side-effects of EGFR inhibitors and their management. Skin Therapy Letter, 16(1), 1-3.
168. Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran Jr, W. J., Wu, Y.-L., & Paz-Ares, L. (2017). Lung cancer: current therapies and new targeted treatments. The Lancet, 389(10066), 299-311.
169. Howlader, N., Noone, A. M., Krapcho, M., Miller, D., Brest. A., Yu, M., … & Cronin, K. A. (2019). SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD
170. Lacouture, M. E. (2013). Dermatologic Principles and Practice in Oncology: Conditions of the Skin, Hair, and Nails in Cancer Patients: John Wiley & Sons.
171. Lacouture, M. E. (2016). Management of Dermatologic Toxicities Associated With Targeted Therapy. Journal of the Advanced Practitioner in Oncology, 7(3), 331–334.
172. Laing, G. M., & Kerr, K. M. (2018). The 2015 World Health Organisation Classification of Lung Cancer. In P. T. Cagle, T. C. Allen, M. B. Beasley, L. R. Chirieac, S. Dacic, A. C. Borczuk, K. M. Kerr, L. M. Sholl, B. Portier, & E. H. Bernicker (Eds.), Precision Molecular Pathology of Lung Cancer (pp. 57-75). Cham: Springer International Publishing.
173. Liu, T. C., Jin, X., Wang, Y., & Wang, K. (2017). Role of epidermal growth factor receptor in lung cancer and targeted therapies. American Journal of Cancer Research, 7(2), 187-202.
174. Lupu, I., Voiculescu, N., Bacalbasa, N., Cojocaru, I., Vrancian, V., & Giurcaneanu, C. (2016). Cutaneous complications of molecular targeted therapy used in oncology. Journal of Medicine and Life, 9(1), 19-25.
175. Lupu, I., Voiculescu, V. M., Bacalbasa, N., Prie, B. E., Cojocaru, I., & Giurcaneanu, C. (2015). Cutaneous adverse reactions specific to epidermal growth factor receptor inhibitors. Journal of Medicine and Life, 8 Spec Issue, 57-61.
176. National Cancer Institute. (2010). Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. Retrieved from https://evs.nci.nih.gov/ftp1/CTCAE/About.html
177. National Cancer Institute. (2018, Sep). Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™). Retrieved from https://healthcaredelivery.cancer.gov/pro-ctcae/overview.html
178. National Comprehensive Cancer Network. (2019a). NCCN GUIDELINES FOR SUPPORTIVE CARE - Distress Management (Version 3.2019). Retrieved from https://www.nccn.org/professionals/physician_gls/PDF/distress.pdf
179. National Comprehensive Cancer Network. (2019b). Non-Small Cell Lung Cancer (Version 4.2019). Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf
180. National Comprehensive Cancer Network. (2019c). Small Cell Lung Cancer (Version 1.2019). Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/sclc_blocks.pdf
181. Orem, L. M. (1995). Nursing: Concept of practice (5th ed.).St. Louis, MO: Mosby.
182. Pakhomov, S. V., Jacobsen, S. J., Chute, C. G., & Roger, V. L. (2008). Agreement between patient-reported symptoms and their documentation in the medical record. American Journal of Managed Care, 14(8), 530-539.
183. Pigkou, K., Alikari, V., Papathanasiou, I., Theophilou, P., Lavdaniti, M., Zyga, S., & Fradelos, E. (2018). Assessment of psychological distress and quality of life in lung cancer patients receiving chemotherapy: A single center experience. Progress in Health Sciences, 8(1), 126-133. doi:10.5604/01.3001.0012.1144
184. Rosenthal, R., & Rosnow, R. L. (1991). Essentials of behavioral research: Methods and data analysis. New York: McGraw-Hill Humanities Social.
185. Wagner, L. I., & Lacouture, M. E. (2007). Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park, NY), 21(11 Suppl 5), 34-36.
186. World Health Organization. (2018, Jun). Measuring Quality of Life. Retrieved from http://www.who.int/healthinfo/survey/whoqol-qualityoflife/en/
187. World Health Organization. (2018, Sep). Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. Retrieved from https://www.who.int/cancer/PRGlobocanFinal.pdf